Mette Vesterhus, Johannes Roksund Hov, Anders Holm, Erik Schrumpf, Ståle Nygård, Kristin Godang, Ina Marie Andersen, Sigrid Næss, Douglas Thorburn, Francesca Saffioti, Morten Vatn, Odd Helge Gilja, Fridtjof Lund‐Johansen, Trygve Syversveen, Knut Brabrand, Albert Parés, Cyriel Y. Ponsioen, Massimo Pinzani, Martti Färkkilä, Bjørn Moum, Thor Ueland, Helge Røsjø, William Rosenberg, Kirsten Muri Boberg, Tom H. Karlsen – 1 April 2015 – There is a need to determine biomarkers reflecting disease activity and prognosis in primary sclerosing cholangitis (PSC).

Juling Ji, Tobias Eggert, Anuradha Budhu, Marshonna Forgues, Atsushi Takai, Hien Dang, Qinghai Ye, Ju‐Seog Lee, Ji Hoon Kim, Tim F. Greten, Xin Wei Wang – 1 April 2015 – Hepatocellular carcinoma (HCC) patients suffer from a poor survival rate and a high incidence of postoperative recurrence. The hepatic microenvironment plays a significant role in the initiation, progression, and recurrence of HCC; however, the causal mechanisms of these phenomena are unclear.

Silvia Udali, Patrizia Guarini, Sara Moruzzi, Andrea Ruzzenente, Stephanie A. Tammen, Alfredo Guglielmi, Simone Conci, Patrizia Pattini, Oliviero Olivieri, Roberto Corrocher, Sang‐Woon Choi, Simonetta Friso – 1 April 2015 – In addition to DNA methylation, hydroxymethylation of DNA is recognized as a novel epigenetic mark. Primary liver cancers, i.e., hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC), are highly prevalent but epigenetically poorly characterized, so far.

Akihiko Soyama, Mitsuhisa Takatsuki, Masaaki Hidaka, Hajime Imamura, Tamotsu Kuroki, Susumu Eguchi – 30 March 2015

Giammauro Berardi, Federico Tomassini, Roberto Ivan Troisi – 30 March 2015 – Living donor liver transplantation is a valid alternative to deceased donor liver transplantation, and its safety and feasibility have been well determined. Minimally invasive living donor hepatectomy (MILDH) has taken some time to be accepted because of inherent technical difficulties and the highly demanding surgical skills needed to perform the procedure, and its role is still being debated.

Laia Tolosa, Silvia López, Eugenia Pareja, María Teresa Donato, Anne Myara, Tuan Huy Nguyen, José Vicente Castell, María José Gómez‐Lechón – 30 March 2015 – Crigler‐Najjar type 1 disease is a rare inherited metabolic disease characterized by high levels of unconjugated bilirubin due to the complete absence of hepatic uridine diphosphoglucuronate–glucuronosyltransferase activity. Hepatocyte transplantation (HT) has been proposed as an alternative treatment for Crigler‐Najjar syndrome, but it is still limited by the quality and the low engraftment and repopulation ability of the cells used.

Julio A. Gutierrez, Andres F. Carrion, Danny Avalos, Christopher O'Brien, Paul Martin, Kalyan Ram Bhamidimarri, Adam Peyton – 30 March 2015 – Recurrent hepatitis C virus (HCV) infection occurs universally in the allograft in the absence of effective antiviral therapy before liver transplantation (LT). Antiviral therapy with sofosbuvir and simeprevir has proven to be highly effective and well tolerated in the nontransplant setting for treatment of HCV genotype 1 infection; therefore, we sought to evaluate the efficacy and safety of this regimen in LT recipients with recurrent HCV infection.

Weiliang Xia, Qinghong Ke, Ye Wang, Xiaowen Feng, Haijun Guo, Weilin Wang, Min Zhang, Yan Shen, Jian Wu, Xiao Xu, Sheng Yan, Shusen Zheng – 30 March 2015 – Donation after cardiac death (DCD) liver grafts are associated with inferior clinical outcomes and high discard rates because of poor graft quality. We investigated the predictive value of DCD liver biopsy for the pretransplant graft quality evaluation. DCD liver transplants that took place between October 2010 and April 2014 were included (n = 127).

John G. O'Grady – 30 March 2015

Kelly M. Collins, William C. Chapman – 30 March 2015